Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jul 22, 2026
China Pharma Holdings, Inc. (CPHI)
A forensic read on China Pharma Holdings, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-3.9
Altman Z-score
Clean
Earnings quality
5
Forensic signals
-14.0%
ROE
-8.5%
Revenue growth
Financial health / Altman Z-score above is based on book value, not market value — this free snapshot doesn't pull live market data. Treat it as a rough read, not the final word.
China Pharma Holdings, Inc. earns a F (Poor — capital at risk) forensic quality grade, and its Altman Z-score is -3.9, placing it in the Distress zone (based on book value, not market value, since this free snapshot doesn't pull live market data — treat this zone as a rough read, not the final word). 5 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+97.0%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +97.0% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 21% of net operating assets, diverging from the balance-sheet accrual read.
-10.4%
FY2025
Return on invested capital.Return on invested capital is -10.4% in the latest fiscal year and rising from -93% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
166d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 127 to 166 FY2024→FY2025 (against cost of goods sold; inventory -28% vs -34% in cost of sales). Inventory is building a little faster than sales — watch for markdowns.
+0.1%/yr
FY2011–FY2015
Share count.Diluted share count changed +0% over the last 4 years to FY2015 (+0.1%/yr). Roughly flat — buybacks are about offsetting stock comp, not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.
$17M
FY2019–FY2019
Goodwill impairments.
Key fundamentals
Latest Revenue$4.1M
Revenue Growth YoY-8.5%
Revenue CAGR (3yr)-20.0%
Net Margin-76.9%
Free Cash Flow$107,321.00
Return on Equity-14.0%
Debt / Equity0.06x
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on China Pharma Holdings, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about CPHI's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown
Data from SEC EDGAR public filings · metrics as of Jul 22, 2026. Forensic signals flag probability, not certainty.
China Pharma Holdings, Inc. (CPHI) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Took $17M of goodwill writedowns across 1 year (FY2019 ($17M)). Writedowns mean past acquisitions underperformed what was paid for them — worth weighing on capital-allocation skill.